NASDAQ:EGLT - Egalet Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.33 0.00 (0.00 %) (As of 05/20/2019 04:00 PM ET)Previous Close$0.3273Today's Range$0.3273 - $0.327352-Week Range$0.0310 - $1.57VolumeN/AAverage Volume853,425 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania. Receive EGLT News and Ratings via Email Sign-up to receive the latest news and ratings for EGLT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EGLT Previous Symbol CUSIPN/A CIK1586105 Webwww.egalet.com Phone610-833-4200Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Egalet (NASDAQ:EGLT) Frequently Asked Questions What is Egalet's stock symbol? Egalet trades on the NASDAQ under the ticker symbol "EGLT." How were Egalet's earnings last quarter? Egalet (NASDAQ:EGLT) posted its quarterly earnings data on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.06. The specialty pharmaceutical company earned $7.44 million during the quarter, compared to the consensus estimate of $8.64 million. View Egalet's Earnings History. What price target have analysts set for EGLT? 2 brokers have issued 1 year price targets for Egalet's stock. Their forecasts range from $1.50 to $1.50. On average, they anticipate Egalet's stock price to reach $1.50 in the next year. This suggests a possible upside of 358.3% from the stock's current price. View Analyst Price Targets for Egalet. What is the consensus analysts' recommendation for Egalet? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Egalet in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Egalet. Has Egalet been receiving favorable news coverage? Media coverage about EGLT stock has been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Egalet earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the company's share price in the next few days. Who are some of Egalet's key competitors? Some companies that are related to Egalet include Advanced Accelerator Application (AAAP), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ) and ERBA Diagnostics (ERBA). What other stocks do shareholders of Egalet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Egalet investors own include Novavax (NVAX), Palo Alto Networks (PANW), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Ocular Therapeutix (OCUL), Trevena (TRVN), 22nd Century Group (XXII), Portola Pharmaceuticals (PTLA), Synergy Pharmaceuticals (SGYP) and Overstock.com (OSTK). Who are Egalet's key executives? Egalet's management team includes the folowing people: Mr. Robert S. Radie, Pres, CEO & Director (Age 55)Mr. Stanley J. Musial, Exec. VP, CFO & Sec. (Age 57)Dr. Mark Strobeck, Exec. VP & COO (Age 47)Ms. Barbara A. Carlin, Sr. VP & Chief Accounting Officer (Age 43)Dr. Karsten Lindhardt M.Sc., Ph.D., Chief Scientific Officer (Age 46) How do I buy shares of Egalet? Shares of EGLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Egalet's stock price today? One share of EGLT stock can currently be purchased for approximately $0.3273. What is Egalet's official website? The official website for Egalet is http://www.egalet.com. How can I contact Egalet? Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected] MarketBeat Community Rating for Egalet (NASDAQ EGLT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 347 (Vote Outperform)Underperform Votes: 225 (Vote Underperform)Total Votes: 572MarketBeat's community ratings are surveys of what our community members think about Egalet and other stocks. Vote "Outperform" if you believe EGLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: What does the Producer Price Index (PPI) tell investors? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.